论文部分内容阅读
芦氟沙星(Rufloxacin)化学名为9-氟-10(N-4-甲基哌嗪基)-7-氧-2,3-二氢-7H-吡啶骈[1,2,3-de][1,4]苯骈噻嗪-6-羧酸盐酸盐,是新一代喹诺酮类的高效广谱抗菌药,1992年首先在意大利上市,目前英、法、德、美等国已进人三期临床试验,其特点为抗菌谱广,半衰期长,每天只需给药一次。主要适用于由敏感性致病菌所致的下呼吸道系统和泌尿生殖系统感染。芦氟沙星片剂在我国已由武汉滨湖制药厂率先研制成功,并用于临床,目前国内尚未见有关芦氟沙星片剂含量测定的报道。本文用紫外分光光度法就芦氟沙星片的含量进行了实验研究,现报道如下:
The chemical name of Rufloxacin is 9-fluoro-10 (N-4-methylpiperazino) -7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de ] [1,4] benzothiazine-6-carboxylic acid hydrochloride, is a new generation of quinolones broad-spectrum antimicrobials, first listed in Italy in 1992, at present, Britain, France, Germany, the United States and other countries have entered Phase III clinical trials, which are characterized by broad antibacterial spectrum, long half-life, just given once a day. Mainly applied to the lower respiratory tract caused by susceptible pathogens and genitourinary infections. Rufloxacin tablet in our country has been the first developed by the Binhu Pharmaceutical Factory in Wuhan, and used in clinical, at present there has been no report about the content of rufloxacin tablets. In this paper, UV spectrophotometry rufloxacin tablets content of the experimental study are reported as follows: